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Abstract
Progesterone-based injectable hormonal contraceptives (HCs) potentially modulate genital barrier 
integrity and regulate the innate immune environment in the female genital tract, thereby 
enhancing risk for STIs or HIV infection. We investigated the effects of injectable HC use on 
concentrations of inflammatory cytokines and other soluble factors associated with genital 
epithelial repair and integrity. The concentrations of 42 inflammatory, regulatory, adaptive, 
growth factors and hematopoetic cytokines, five matrix metalloproteinases (MMPs), and four 
tissue inhibitors of metalloproteinases (TIMPs) were measured in cervicovaginal lavages (CVLs) 
from 64 HIV negative women using injectable HCs and 64 control women not using any HCs, in a 
matched case-control study. There were no differences between groups in the prevalence of 
bacterial vaginosis (BV; nugent score ≥7), or common sexually transmitted infections (STIs). In 
multivariate analyses adjusting for condom use, sex work status, marital status, BV and STIs, 
median concentrations of chemokines (eotaxin, MCP-1, MDC), adaptive cytokines (IL-15), 
growth factors (PDGF-AA) and a metalloproteinase (TIMP-2) were significantly lower in CVLs 
from women using injectable HCs than controls. In addition, pro-inflammatory cytokine IL-12p40 
and chemokine fractalkine were less likely to have detectable levels in women using injectable 
HCs compared to those not using HCs. We conclude that injectable HC use was associated with an 
immunosuppressive female genital tract innate immune profile. While the relationship between 
injectable HC use and STI or HIV risk is yet to be resolved, our data suggest that injectable HCs 
effects were similar between STI positive and STI negative participants.
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1.0 Introduction
Internationally, hormonal contraceptives (HCs) are widely used by women to prevent 
unplanned pregnancies. In South Africa, more than half of women aged 15–49 years old use 
depot medroxyprogesterone acetate (DMPA) or norethisterone enanthate (Net-EN), with 
more than 3 times the number of women using DMPA than Net-EN (Sibeko et al., 2011). 
DMPA is an aqueous microcrystalline suspension (150mg/ml) administered by 
intramuscular depot injection every three months while NET-EN injection contains 
200mg/ml of norethisterone that is effective for two months as a contraception ((Bhathena, 
2001, Elder, 1984, Fraser and Weisberg, 1981). DMPA primarily provides contraceptive 
protection by suppressing natural cyclic fluctuations of female sex hormones resulting in a 
hypoestrogenic state (Jeppsson et al., 1982). In addition, DMPA induces atrophy of the 
endometrium by decreasing glycogen content needed to provide energy for the development 
of the blastocyst after the morula has entered the uterine cavity (Hatcher et al., 2011, Mishell 
et al., 1968). Less is known about then endogenous effects of Net-EN.
High-dose DMPA use is common in the simian immunodeficiency virus (SIV) vaginal 
challenge models because it results in thinning of the vaginal epithelium, which enhances 
genital SIV infection (Abel et al., 2004, Trunova et al., 2006, Wieser et al., 2001, Marx et 
al., 1996). The role of DMPA in increasing risk of HIV infection is contentious. While some 
studies have reported such risks (Hel et al., 2010, Morrison et al., 2010, Ungchusak et al., 
1996, Baeten et al., 2007, Heffron et al., 2012, Kumwenda et al., 2008), others have found 
no association (Kiddugavu et al., 2003, Kleinschmidt et al., 2007, Myer et al., 2007, Reid et 
al., 2010, Stringer et al., 2009). The impact of DMPA on genital epitheial barrier intergrity is 
similary contentius (Kiddugavu et al., 2003, Myer et al., 2007).
In addition to potentially increasing HIV acquisition risk, DMPA has been associated with 
an increased risk of Chlamydia trachomatis infection and at decreased risk of aquiring other 
sexually transmitted infections (STIs) such as Trichomonas vaginalis and bacterial vaginosis 
(BV) (Baeten et al., 2001, van de Wijgert et al., 2013).
It has been hypothesised that DMPA might increase HIV aquisition risks by changing the 
inflammatory or chemotactic environment of the genital mucosa so as to increase the 
recruitment of HIV susceptible immune cells to the mucosa (Ildgruben et al., 2003, Miller et 
al., 2000, Wieser et al., 2001, Wira et al., 2011, Wira and Veronese, 2011). However, 
treatment of PBMC with DMPA has been shown to causes reduced production of several 
inflammatory and adaptive cytokines (Huijbregts et al., 2013). At the female genital mucosa, 
suppression of innate immune responses may influence susceptibility to infections. 
Moreover, matrix metalloproteinases (MMPs), which are required during normal 
reproductive processes (such as menstruation) for extracellular matrix degradation and tissue 
remodeling in the endometrial compartment of the upper genital tract (Lockwood and 
Schatz, 1996, Rodgers et al., 1994, Rodgers et al., 1993, Birkedal-Hansen, 1995, Cawston, 
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1995), may influence epithelial barrier repair in the lower genital tract. MMPs are regulated 
by specific tissue inhibitors of metalloproteinases (TIMPs) (Fernandez-Catalan et al., 1998, 
Gomis-Ruth et al., 1997), which may similarly be involved in maintainence of the lower 
reproductive tract barrier.
Defining the impact of injectable HCs on female genital tract innate immunity in relation to 
susceptibility to STIs or BV, will provide important insights into biological co-factors 
influencing HIV risk in women. The aim of this study was to compare concentrations of 
genital tract soluble immune mediators (including cytokines, MMPs and TIMPs) between 
women using long-acting injectable HCs and women not using HCs, while accounting for 
BV and common STIs.
2.0 Materials and methods
2.1 Study design, participants and sample collection
Our study included 64 HIV-uninfected women using injectable HCs (DMPA or Net-EN) 
and 64 women not using HCs, enrolled into the prospective CAPRISA 002 observational 
cohort study of acute HIV infection conducted at the Centre for the AIDS Programme of 
Research in South Africa (CAPRISA), in Durban, KwaZulu-Natal Province, South Africa, 
as previously described (Mlisana et al., 2012, van Loggerenberg et al., 2012). Non-HC users 
were matched to injectable HC users based on age (within 5 years of age) at a 1:1 ratio. 
Demographic and clinical data were collected at enrolment using a structured questionnaire 
administered by a trained counsellor. Although data on type of contraception (injectable 
HCs, combined oral contraceptives (COCs), intrauterine devices (IUDs), condoms, 
diaphrams, foam and jelly, or were sterilised) was collected no information was collected on 
whether the injectable contraceptive being used was DMPA or Net-EN. We therefore report 
on injectable HCs in this study as a combination of DMPA and Net-EN users. Women using 
COC or any other form of hormal contraception were excluded from the study, with an 
exception of IUD user. Laboratory samples, including cervicovaginal lavages (CVLs) were 
collected from each participant at enrolment by gently flushing the cervix and the lateral 
vaginal walls with 10ml sterile normal saline, as previously described by Mlisana et al. 
(2012). Volume of saline recovered after the lavage were not typically recorded. CVLs were 
transported within 4 hours on ice from the site to the laboratory. In the laboratory, CVLs 
were centrifuged, the supernatant collected and stored at −80°C. The protocol for this study 
was approved by the Ethical Review Committees of the University of KwaZulu-Natal and 
University of Cape Town.
2.2 Testing for STIs and BV
At enrollment, vulvovaginal swabs collected from the posterior fornices and lateral vaginal 
walls from each woman were tested for C. trachomatis, Neisseria gonorrhoeae, 
Mycoplasma genitalium, HSV-2 reactivation and T. vaginalis using PCR. Gram stain was 
performed to diagnose BV using Nugent score ≥7 (Mlisana et al., 2012).
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2.3 Cytokine, MMP and TIMP measurements in CVL
Concentrations of cytokines, MMPs and TIMPS were measured in CVLs collected at 
enrollment,. We measured 42 cytokines [including IL-1α, IL-3, IL-9, IL-12p40, IL-15, 
IL-17, epidermal growth factor (EGF), platelet-derived growth factor (PDGF)-AA, 
transforming growth factor (TGF)-α, vascular endothelial growth factor (VEGF), eotaxin/
CCL11, FGF-2, FLT3 Ligand (FLT3L), fractalkine/CX3CL1, G-CSF, growth related 
oncogene (GRO) family (CXCL1-CXCL3), IFN-α, IFN-γ-induced protein (IP)-10/CXCL10, 
monocyte chemoattractant protein (MCP)-1/CCL2, MCP-3/CCL7, macrophage-derived 
chemokine (MDC)/CCL22, MIP-1α/CCL3, MIP-1β/CCL4, PDGF-AB/BB, RANTES/
CCL5, soluble CD40 ligand (sCD40L), soluble IL-2 receptor α (sIL-2Rα), TNF-β, IL-1β, 
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-10, IL-12p70, IL-13, GM-CSF, IFN-γ and 
TNF-α]; 4 TIMPs [TIMP-1, -2, -3, -4]; and 5 MMPs [MMP-1, -2, -7, -9 and -10]. The 
Human Cytokine and High Sensitivity LINCOplex Premixed kits (LINCO Research, MO, 
U.S.A.) were used to measure cytokines; and the TIMP Panel 2 and MMP Panel-2 kits were 
used to measure TIMPs and MMPs, respectively (Merck-Millipore, Missouri, U.S.A.). 
CVLs were thawed overnight on ice and filtered by centrifugation using 0.2 μm cellulose 
acetate filters (Sigma, U.S.A.). All markers were measured in undiluted CVL, except for 
MMP-9 (which was measured at 50-fold dilution), on a Bio-Plex 100 system (Bio-Rad 
Laboratories Inc®, Hercules, California). Bio-Plex manager software (version 5.0; Bio-Rad 
Laboratories Inc®) was used to analyse the data and all analyte concentrations were 
extrapolated from the standard curves using a 5 parameter logistic (PL) regression equation. 
Analyte concentrations that were below the lower limit of detection of the assay were 
reported as the mid-point between zero and the lowest concentration measured for each 
analyte. For IL-8, only two samples had readings above the upper limit of detection. For 
these two samples, IL-8 concentrations were reported as halfway between the highest 
concentration and the upper limit of the standard curve.
2.4 Statistical analyses
Fisher’s exact test was used to compare proportions, while a t-test was used to compare ages 
between groups. To assess the effect of injectable HCs on cytokine levels, linear regression 
analysis was used. Cytokines that were undetectable in at least a third of women (IL-2, 
IL-2Rα, IL-3, IL-4, IL-10, IL-12p40, IL-12p70, IL-13, Fractalkine, MIP-1α, IFN-α, EGF, 
TFG-α, FGF-2, PDGF-AB/BB and MMP-2) were dichotomised (i.e. being rated as either 
present or absent in each woman) and logistic regression was used to estimate the effect of 
injectable HCs on the detectability of these cytokines. Linear and logistic regression 
analyses were adjusted for sex worker status, age, condom use at last sex act, BV and STIs. 
In addition, interaction terms were tested to assess whether injectable HCs modified the 
effect of STIs on cytokine concentrations. Because of the small number of women testing 
positive for cervical STIs, C. trachomatis, N. gonorrhoeae or M. genitalium, these STIs 
were grouped together [Gonorrhea-Chlamydia-Mycoplasma (GCM)] for the purposes of this 
analysis. Statistical analyses were performed using SAS version 9.3 (SAS Institute Inc., 
Cary).
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This study included a total of 128 women, 64 of whom were non-HC users (including 1 
woman using an IUD) and 64 of whom were injectable HC users (either DMPA or Net-EN) 
(Table 1). Of these 128 women, 79.7% were self-reported sex workers and this did not differ 
between groups. Women using injectable HCs were less likely to be single than those not 
using injectable HCs (0.0% compared to 4.7%; p=0.057), and less likely to report having 
multiple partners (52.4% versus 65.6%), although this was not significant. Condom use at 
last sex act was similar among women using injectable HC and of women not using HCs 
(53.1% vs 65.6%, p=0.208).
3.1 Prevalence of BV and STIs in injectable HC versus non-HC users
To investigate the association between injectable HC use and STIs, the prevalence of C. 
trachomatis, T. vaginalis and BV in women using injectable HCs was compared to those 
who were not using HCs. At baseline (Table 1), more than half of the women in this cohort 
had BV (nugent score ≥7), and this did not differ significantly between women not using 
HCs and those using injectable HCs (51.6% and 50.8%, respectively; p=1.000). Nineteen 
percent of women were infected with T. vaginalis and this was similar between groups 
(19.1% for injectable HC users and 18.8% for non-HC users; p=1.000). The prevalence of C. 
trachomatis (6.3%), N. gonorrhoeae (6.3%), M. genitalium (1.6%), and HSV-2 (2.4%) were 
relatively low in this cohort and were also similar between groups (Table 1).
3.2 Impact of injectable HCs on innate immune factors in the female genital tract
To better understand how injectable HC use influenced the genital tract innate environment, 
the concentrations of cytokines, chemokines, growth factors and markers of tissue repair or 
remodelling (MMPs and TIMPs) were compared in CVL from women using injectable HCs 
and those not using HCs (Table 2). Of the 42 chemokines, growth factors and inflammatory 
cytokines that were measured, 5/42 (11.9%) had significantly decreased median 
concentrations in the CVL of women using injectable HCs than those not using HCs, after 
adjusting for age, condom use, sex worker status, marital status, STIs, and BV. This 
included several chemokines, including eotaxin [beta-coefficient (β)=−0.334, p=0.004], 
MCP-1 (β=−0.359, p=0.015), MDC (β=−0.364, p=0.003); the growth factor PDGF-AA (β=
−0.506, p=0.001); the adaptive cytokine IL-15 (β=−0.240, p=0.038). In addition, pro-
inflammatory cytokine IL-12p40 (β=−1.059, p=0.009) and chemokine fractalkine (β=
−0.910, p=0.028) were less likely to be detectable in women using injectable HCs compared 
to those not using HCs. While linear regression was used to estimate the effect of injectable 
HCs on concentrations of eotaxin, MCP-1, and MDC, a logistic regression model was fitted 
to estimate the effect of injectable HC use on the detectability of fractalkine and IL-12p40 
because the concentrations of these cytokines were undetectable in at least a third of the 
women in this study. Furthermore, the median concentration of TIMP-2 was significantly 
lower in women using injectable HCs than those not using HCs (β=−0.207, p=0.027). In 
contrast, no differences were observed in MMP concentrations. None of the cytokines, 
chemokines, growth factors and markers of tissue repair concentrations were significantly 
different between groups.
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3.3 Impact of BV and STIs on cytokines in injectable HC versus non-HC users
Because we found that injectable HC use resulted in lower median concentration of genital 
tract cytokines from several different functional classes (Table 2), we assessed whether there 
were interactions between injectable HCs and cytokine concentrations in responses to BV or 
STIs in the female genital tract. We did not observe any significant interactions between 
injectable HC use and cytokine responses to BV (Supplementary Table 1). T. vaginalis also 
had a limited interaction with injectable HC, with only Flt3L demonstrating a significant 
result (β-estimate of −0.194 in the injectable group vs 0.338 in the non-injectable group, 
p=0.048, Supplementary Table 2). However, we found significant interactions between 
gonorrhea, chlamydia or mycoplasma (GCM) infections and injectable HC use for certain 
cytokines, with TNF-β (p=0.022), IL-5 (p=0.015), IL-7 (p=0.036) and TIMP-4 (p=0.003), 
with GCM positive women on injectable HC having increased median concentrations of 
these cytokines in the CVL, compared to the effect of GCM positivity on cytokine 
concentrations within the non-HC users (Figure 1, supplementary Table 3). Furthermore, 
IL-12p40 (p=0.061) and Fractalkine (p=0.069) showed a trend towards being elevated in the 
GCM positive women using injectable HCs compared to non-HC users. However, none of 
these associations remained significant after adjusting for multiple comparisons.
4.0 Discussion
We found that median concentrations of several cytokines and soluble factors (including 
several chemokines, pro-inflammatory and adaptive cytokines, growth factors and TIMP 
were reduced in CVLs of women using injectable HC compared to women who were not 
using HC, after controlling for age, condom use, sex work, STIs and BV. Despite this 
reduction of innate immune responses in the female genital tracts of women using injectable 
HCs, no differences in prevalence of BV, or STIs (including C. trachomatis, N. gonorrhoea, 
T. vaginalis, M. genitalium, or HSV-2) were found.
Although some animal studies using high dose DMPA, have demonstrated that DMPA has 
immunosuppressive properties both systemically and in the reproductive tract (Abel et al., 
2004, Bamberger et al., 1999, Genesca et al., 2007, Gillgrass et al., 2003, Hel et al., 2010, 
Hughes et al., 2008, Huijbregts et al., 2013, Kleynhans et al., 2013, Kleynhans et al., 2011, 
Koubovec et al., 2004, Trunova et al., 2006), fewer studies have been conducted in humans 
and these have predominantly been performed using PBMCs (Hughes et al., 2008, 
Kleynhans et al., 2011). With the exception of Huijbregts et al. (2013) who reported reduced 
cervicovaginal production of IFN-α in women using injectable HCs, the other human studies 
suggested that DMPA use may actually increase inflammation within the female genital 
tract (Baeten et al., 2001, Ghanem et al., 2005). In this study, decreased chemotactic 
cytokine (including eotaxin, fractalkine, MCP-1 and MDC in the multivariate analyses) 
concentrations observed in women using HCs might influence the trafficking of immune 
cells to the female genital tract. Fractalkine has been reported to play a role to the 
recruitment of immune cells to the endometrium, which may be influenced by the presence 
of DMPA (Hannan et al., 2004). Although these associations potentially suggest HC 
interference with chemotaxis, we have not done the mechanistic studies necessary to test the 
relationship between HCs and trafficking of cells within genital tissues.
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In our interaction term analysis, we hypothesized that HC use had a limited impact on 
cytokine responses to trichomoniasis and gonorrhea, chlamydia and mycoplasma infections, 
but did not modify the relationship between cytokine concentrations and BV. This analysis 
suggested that women with gonorrhea, chlamydia and mycoplasma (GCM) infections who 
were using HCs had greater increases in the concentrations of TNF-β, IL-5, IL-7, TIMP-4, 
IL-12p40 and Fractalkine relative to women with GCM infections who were not using HCs. 
In addition, we found that the effect size of the relationship between T. vaginalis and Flt3L 
concentrations was larger in women using injectable HCs compared to non-HC users. 
However, these associations should be interpreted conservatively as none of these 
associations was significant after adjusting for multiple comparisons and sample sizes for 
these analyses were relatively small.
High dose DMPA administration to macaques is associated with thinning of the vaginal 
epithelium (Abel et al., 2004, Genesca et al., 2007, Trunova et al., 2006, Wieser et al., 
2001). In this study, significantly reduced concentrations of PDGF-AA were found in CVL 
from women using injectable HC compared to women not using injectable HCs. This 
growth factor has been reported to play an important role in restoring the barrier function of 
the female genital tract following injury, and reduced expression may influence the ability of 
the epithelial barrier to be regenerated and repaired (Werner and Grose, 2003). Growth 
factors enhance epithelial repair by stimulating mitosis, spreading and migration of 
epithelial cells in mouse airways (Werner and Grose, 2003), and as such, a decrease in these 
factors could lead to weakened epithelial barriers and reduced epithelial healing in women 
using injectable HCs.
MMPs and TIMPs play an important role in the degradation and remodeling of the 
extracellular matrix in the upper reproductive tract during normal reproductive processes 
(Lockwood and Schatz, 1996, Rodgers et al., 1994, Rodgers et al., 1993, Birkedal-Hansen, 
1995, Cawston, 1995). Previous studies have shown that progesterone suppresses the 
epithelial cell-specific MMPs, working cooperatively with TGF-β to regulate epithelial-
specific MMP-7 expression (Bruner et al., 1995, Osteen et al., 1994). In contrast, in the 
lower reproductive tract, we found no difference between MMP concentrations in women 
using injectable HCs compared to those who were not using HC. Previously, Vincent et al. 
(2002) found that women using DMPA had decreased TIMP-1 and -2 concentrations in their 
endometrial epithelium and an altered local MMP:TIMP balance in their upper reproductive 
tracts compared to women not using HCs. Similarly, we found decreased TIMP-2 
concentrations in secretions from the lower reproductive tracts of women using injectable 
HC compared to those not using HCs. Reduced concentrations of TIMPS may alter the 
MMP/TIMP ratio which could lead to decreased epithelial barrier integrity.
A limitation of our study is that we could not differentiate DMPA from Net-EN users within 
the injectable HC user group although these progestin-based HCs may have distinct 
biological effects. DMPA or NET-EN users may differ behaviourally or systematically from 
women who do not any hormonal contraceptives. In addition, we did not monitor the stage 
of the menstrual cycle in this cohort, nor collect longitudinal data on DMPA or NET-EN use 
prior sampling. This study did not adjust CVL for dilution so absolute concentrations of 
cytokines may have been influenced by this factor.
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We found reductions in CVL concentrations of one proinflammatory cytokine, four 
chemokines, one growth factor, one adaptive cytokine and one TIMP in the lower female 
genital tract of women using injectable HCs. While we are underpowered to demonstrate the 
relationship between injectable HC use and STI or HIV risk, our data suggest that injectable 
HCs effects were similar between STI positive and STI negative participants. Large-scale 
randomized clinical trials assessing the impact of progestin-derivatives (DMPA or Net-EN) 
on local and systemic innate and adaptive immune environment, as well as STIs, are needed 
to further investigate the mechanism(s) by which DMPA or Net-EN might increase risk of 
HIV infection.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Cytokine concentrations in cervicovaginal lavages (CVLs) from women using injectable 
HCs (DMPA or Net-EN) compared to those not using HCs, stratified according to presence 
of discharge causing STIs (C. trachomatis, N. gonnorhoea, M. genitalium; GCM). Dotted 
lines indicate the median concentration of each cytokine, MMP or TIMP in women not 
using HCs and who were GCM negative, as the reference group. ** indicates significant 
interactions between injectable HC use and GCM with p<0.05, while * indicates interactions 
between injectable HC use and GCM with p<0.10.
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Table 1
Baseline demographic and clinical characteristics
Variables Overall Injectable-HCs users Non-HCs users P-value
N 128 64 64
Age (years) 28 (23–36) 28 (23–36) 29 (23–37) 0.653
Marital status [% (n)]
 Single 2.4% (3) 0.0% (0) 4.7% (3) 0.057
 Stable partner 34.7% (44) 41.3% (26) 28.1% (18)
 Married 3.9% (5) 6.4% (4) 1.6% (1)
 Many partners 59.1% (75) 52.4% (33) 65.6% (42)
Sex work [% (n)] 79.7% (102) 79.7% (51) 79.7% (51) 1.000
Education [% (n)]
 <Grade 8 21.9% (28) 21.9% (14) 21.9% (14) 0.972
 Grade 8–10 29.7% (38) 28.1% (18) 31.3% (20)
 Grade 11–12 48.4% (62) 50.0% (32) 46.9% (30)
Condom use [% (n)]
Always use condom with steady partner(s) 25.0% (32) 20.3% (13) 29.7% (19) 0.308
Always use condom with casual partner(s) 53.9% (69) 46.9% (30) 60.9% (39) 0.156
Condom use at last sex act 59.4% (76) 53.1% (34) 65.6% (42) 0.208
Positive test or culture result [% (n)]
 Genital discharge 17.2% (22) 12.5% (8) 21.9% (14) 0.241
 Bacterial vaginosis (Nugent >7) 51.2% (65) 50.8% (32) 51.6% (33) 1.000
 Trichomonas vaginalis 18.9% (24) 19.1% (12) 18.8% (12) 1.000
 Chlamydia trachomatis 6.3% (8) 4.8% (3) 7.8% (5) 0.718
 Neisseria gonorrhoeae 6.3% (8) 1.6% (1) 10.9% (7) 0.062
 Mycoplasma genitalium 1.6% (2) 3.2% (2) 0.0% (0) 0.244
 HSV-2 PCR 2.4% (3) 3.2% (2) 1.6% (1) 1.000
*
Descriptive statistics are reported as percentages (categorical data) or medians and IQRs (continuous data).
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